Výsledky vyhledávání - "Shulian Shang"

Akademický článek

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Autor: Achim Berthele, Michael Levy, Dean M. Wingerchuk, Sean J. Pittock, Shulian Shang, Adrian Kielhorn, Minying Royston, Guido Sabatella, Jacqueline Palace

Publikováno v: Frontiers in Neurology, Vol 14 (2023)

BackgroundCumulative damage from multiple relapses in neuromyelitis optica spectrum disorder (NMOSD) is associated with poor health-related quality of life (HRQoL) and long-term disability in patients positive for anti-aquaporin 4 antibodies (AQP4+).

Externí odkaz: https://doaj.org/article/7dcd6b20c6ed44b39cb3c1f119ab5c3b

Zobrazit plný text záznamu

Supplementary Figure S2 from A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis

Autor: Eva Hernando, Iman Osman, Yongzhao Shao, Farbod Darvishian, Russell Berman, Richard Shapiro, Anna Pavlick, Shulian Shang, Daniel J. Lackaye, Avital Gaziel-Sovran, Lisa Koetz, Judy Zhong, Doug Hanniford

Supplementary Figure S2. This figure depicts brain metastatsis-free and overall survival, as plotted kaplan-meier survival curves, of high- vs low-risk patients (determined by the miRNA signature + stage model) for patients stratified by stage at dia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0b909430d9d5d14bc63bd272cd7380
https://doi.org/10.1158/1078-0432.22458140.v1

Zobrazit plný text záznamu

Data from A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis

Purpose: Brain metastasis is the major cause of mortality among patients with melanoma. A molecular prognostic test that can reliably stratify patients at initial melanoma diagnosis by risk of developing brain metastasis may inform the clinical manag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7b559f37e2892ef1b8d9c22906ae21
https://doi.org/10.1158/1078-0432.c.6523844

Zobrazit plný text záznamu

Akademický článek

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Autor: Douglas L. Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L. Naylor

Publikováno v: Therapeutic Advances in Neurological Disorders, Vol 11 (2018)

Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing–rem

Externí odkaz: https://doaj.org/article/8dc73721ee4e4953a23109e4e4cc0c15

Zobrazit plný text záznamu

Akademický článek

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Autor: Scott D. Newsome, Thomas F. Scott, Douglas L. Arnold, Gereon Nelles, Serena Hung, Yue Cui, Shulian Shang, Maria L. Naylor, Marcelo Kremenchutzky

Publikováno v: Therapeutic Advances in Neurological Disorders, Vol 11 (2018)

Background: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The

Externí odkaz: https://doaj.org/article/0d6383108a324594a228068074ed26f7

Zobrazit plný text záznamu

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Autor: Achim Berthele, Michael Levy, Dean M. Wingerchuk, Sean J. Pittock, Shulian Shang, Adrian Kielhorn, Minying Royston, Guido Sabatella, Jacqueline Palace

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030a5a315bc47770716c93e1f8b34a7c
https://mediatum.ub.tum.de/1707434

Zobrazit plný text záznamu

Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension

Autor: Achim Berthele, Dean Wingerchuk, Kazuo Fujihara, Jacqueline Palace, Michael Levy, Ho Jin Kim, Ichiro Nakashima, Celia Oreja-Guevara, Kai-Chen Wang, Shulian Shang, Marcus Yountz, Sean Pittock

Publikováno v: Neurology. 99:S3-S4

ObjectiveNA.BackgroundEculizumab is well tolerated and significantly reduces relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). We report eculizumab's long-term r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ece8091714f67f08489e828699a5ceca
https://doi.org/10.1212/01.wnl.0000903068.75712.b8

Zobrazit plný text záznamu

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Autor: Jacqueline Palace, Kazuo Fujihara, Achim Berthele, Sean J. Pittock, Michael J. Levy, Shulian Shang, Larisa Miller, R Armstrong, Dean M. Wingerchuk, Celia Oreja-Guevara, Marcus Yountz, Ho Jin Kim, Ichiro Nakashima

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England). 28(3)

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9867587dfe0b866190d7bcb4ccfacc72
https://pubmed.ncbi.nlm.nih.gov/34498507

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání